Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12591261-0,86
KB983984-0,96
PKN143,68143,72-0,55
Msft398,61398,880,00
Nokia11,62511,635-2,14
IBM271,3272,850,00
Mercedes-Benz Group AG47,9347,9450,50
PFE25,725,80,00
10.06.2026 10:47:55
Indexy online
AD Index online
select
AD Index online
 

  • 09.06.2026
Illumina Inc (ILMN.O, NASDAQ Cons)
Závěr k 9.6.2026 Změna (%) Změna (USD) Objem obchodů (USD)
160,03 1,26 1,99 1 455 112
Premarket10.06.2026 10:00:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (USD)
- 150,64 162,00 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.06.2026
Popis společnosti
Obecné informace
Název společnostiIllumina Inc
TickerILMN
Kmenové akcie:Ordinary Shares
RICILMN.O
ISIN-
Poslední známé roční výsledky28.12.2025
Poslední známé čtvrtletní výsledky29.03.2026
Počet zaměstnanců k 28.12.2025 8 600
Akcie v oběhu k 24.04.2026 151 300 000
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice5200 Illumina Way
MěstoSAN DIEGO
PSČ92122
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 026 587 581
Fax13026555049

Business Summary: Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Financial Summary: BRIEF: For the three months ended 29 March 2026, Illumina Inc revenues increased 5% to $1.09B. Net income increased 2% to $134M. Revenues reflect Consumables segment increase of 4% to $797M, Services and Other revenue segment increase of 8% to $174M, Europe segment increase of 22% to $356M, Americas segment increase of 4% to $590M. Net income was partially offset by Other expense, net - Balancing value decrease from $30M (income) to $47M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSOther Financial Vehicles
NAICS2007Analytical Laboratory Instrument Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Analytical Laboratory Instrument Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICAnalytical Instruments
SICAnalytical Instruments
SICCommercial Physical Research
SICInvestment Offices, Nec



  • Poslední aktualizace: 10.06.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorJacob Thaysen5025.09.202325.09.2023
Chief Financial OfficerAnkur Dhingra5015.04.202415.04.2024
Chief People OfficerPatricia Leckman6201.01.2023
Chief Technology OfficerSteven Barnard6609.08.202309.08.2023
Chief Legal OfficerScott Davies5603.10.2024
Chief of Global OperationsKevin Pegels5901.01.2021
Chief Strategy and Corporate Development OfficerJakob Wedel5409.04.202409.04.2024